Abstract: The present invention relates to methods for detecting a malignant tumor in an individual by means of determining the Vimentin variant 3 (Vim3) level in the individual's blood serum S and/or the accumulation of Vim3 polypeptide in cell nuclei. Furthermore, the present invention refers to an antineoplastic agent for use in a method for treating an individual bearing a malignant tumor, wherein said antineoplastic agent is a Vim3 inhibitor and/or wherein the malignant tumor is endothelin B receptor negative.

Abstract: A device for the preparation of a Descemet's membrane-endothelium graft includes a bowl with an inner bottom and a sidewall surrounding the bottom, particularly the bowl being configured to receive a fluid and a Descemet's membrane-endothelium graft or a donor cornea graft comprising a Descemet's membrane-endothelium graft floating in the fluid, a preparation area positioned in a first part of the inner bottom of the bowl, particularly for receiving and preparing the graft prior to transport, a transfer area positioned in a second part of the inner bottom between the preparation area and an outlet opening in the sidewall, particularly the opening being entirely positioned below the upper rim of the sidewall.

Abstract: A device for the transplantation of a Descemet's membrane includes a longitudinal tube having an inner cavity, an inlet opening through which it is possible to introduce the Descemet's membrane into the device, and an outlet opening through which it is possible to eject the Descemet's membrane from the device, especially into the anterior eye chamber of a patient, wherein the device also includes, at least in the region of the outlet opening, a separation element which protrudes from the inner wall region of the tube into the cavity, especially a first separation element, the separation element dividing the cavity at least regionally, in particular dividing it in a region close to the separation element.

Abstract: The invention relates to CPAP-tubulin inhibitors having the general formula (1) or a physiologically acceptable salt thereof; and their use as cancer therapeutics.

Abstract: The present invention is related to a structural protein of a parvovirus with an amino acid insertion at the insertion site I-453, a library comprising the protein, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a vector, virus or cell comprising the nucleic acid, a process for the preparation of the protein, a medicament comprising the protein, nucleic acid or multimeric structure as well as methods and uses involving the protein, nucleic acid or multimeric structure.

Abstract: The present invention is related to a method for identifying a parvovirus mutated structural protein capable of specifically binding to a binder for an antigen, a parvovirus mutated structural protein which comprises at least one B-cell epitope heterologous to the parvovirus, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a virus or cell comprising the protein, a method of preparing the protein, a medicament comprising the protein, nucleic acid or multimeric structure and its use.

Abstract: The invention relates to CPAP-tubulin inhibitors having the general formula (1) or a physiologically acceptable salt thereof; and their use as cancer therapeutics.

Abstract: The present invention is related to a structural protein of a parvovirus with an amino acid insertion at the insertion site I-453, a library comprising the protein, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a vector, virus or cell comprising the nucleic acid, a process for the preparation of the protein, a medicament comprising the protein, nucleic acid or multimeric structure as well as methods and uses involving the protein, nucleic acid or multimeric structure.

Abstract: The present invention is related to a structural protein of a parvovirus with an amino acid insertion at the insertion site I-453, a library comprising the protein, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a vector, virus, or cell comprising the nucleic acid, a process for the preparation of the protein, a medicament comprising the protein, nucleic acid, or multimeric structure as well as methods and uses involving the protein, nucleic acid, or multimeric structure.

Abstract: A device and method for providing stimulation signals that reset the phase of the neuronal activity of neurons in a patient's brain. The device includes a control unit; and a stimulation unit that has a plurality of stimulation elements, and each stimulation element generates visual stimulation signals that reset the phase of the neuronal activity of the neurons when the signals are taken up via an eye of a patient and transmitted to neurons that are exhibiting a pathologically synchronous and oscillatory neuronal activity. The control unit is further capable of actuating the stimulation unit such that the stimulation elements generate the visual stimulation signals with a time offset in respect to one another and/or with differing phase and/or with differing polarity.

Abstract: The present invention provides novel marker genes for the specific identification and characterization of human suppressive and/or regulatory T cells including natural, adaptive, and expanded CD4+CD25+FOXP3+ T cells in healthy individuals as well as tumor patients or patients with autoimmune diseases.

Abstract: The present invention provides acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes which can deliver carbon monoxide to a physiological target, wherein release of carbon monoxide can be enzymatically-triggered. The present invention also provides for methods of manufacturing the enzymatically-triggered carbon monoxide releasing molecules and methods for their use.

Abstract: A process for operating an internal combustion engine or a nozzle includes producing a fuel mixture in-situ. The fuel mixture consists of a polar component A, a nonpolar fuel component B, an amphiphilic component C, and an auxiliary component D. The fuel mixture is produced in a high-pressure region of an injection system of an internal combustion engine or of a nozzle within 10 seconds of an injection operation. The fuel mixture is injected into the internal combustion engine or the nozzle. A pressure is in a range of from 100 to 4,000 bar.

Abstract: The invention relates to an organic light-emitting diode, known under the abbreviation OLED, and to a method for the production of such an organic light-emitting diode. According to the invention, an OLED or organic light-emitting diode having an emitter layer (5) is produced, said emitter layer emitting white light in particular. The emitter layer (5) is arranged within a lossy, optical resonator. The optical path length between the two reflecting layers of the resonator determines the color of the light emitting from the optical resonator and, consequently, from the light-emitting diode. In order to be able to create a variety of colors, there must be different optical path lengths between the two reflecting surfaces. The correspondingly different distances can be produced in only one work step, in contrast to the prior art, by a photolithographic method.

Abstract: A device and method for desynchronizing a patient's neuronal brain activity involving a neuron population firing in a pathologically synchronized manner. The device includes a stimulation unit configured to generate an acoustic stimulation signal to stimulate the neuron population when the acoustic stimulation signal is aurally received by the patient. Furthermore, the acoustic stimulation signal has a first frequency and a second frequency, with the first frequency provided to reset the phase of the neuronal brain activity in a first sub-population of the stimulated neuron population, and the second frequency provided to reset the phase of the neuronal brain activity in a second sub-population of the stimulated neuron population.

Abstract: The present invention provides a compound comprising a general formula 1: In general formula 1, X is at least one of O and S. A is a ring bridge. Y1 is at least one of H, alkyl, fluoroalkyl, aryl and heteroaryl. Z1, Z2, Z3 are, individually or alternatively, at least one of H, carbonyl, OH, O-alkyl, O-acyl, N—R1R2 (where R1 or R2 are, individually or alternatively, at least one of H, alkyl, acyl, and sulfonyl), alkyl, acyl, fluoroalkyl, aryl, and heteroaryl. R1 is at least one of alkyl, acyl, alkoxycarbonyl, aryloxycarbonyl, and aminocarbonyl. R2 is at least one of H, alkyl, aryl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, aryloxycarbonyl, alkylsulfonyl, arylsulfonyl, aminoacyl and peptidyl. The present invention furthermore relates to the use of the compound as a pharmaceutical active compound, and to the use of the pharmaceutical active compound to treat bacterial diseases, neurodegenerative diseases and tumors.

Abstract: A device and method for desynchronizing a patient's neuronal brain activity involving a neuron population firing in a pathologically synchronized manner. The device includes a stimulation unit configured to generate an acoustic stimulation signal to stimulate the neuron population when the acoustic stimulation signal is aurally received by the patient. Furthermore, the acoustic stimulation signal has a first frequency and a second frequency, with the first frequency provided to reset the phase of the neuronal brain activity in a first sub-population of the stimulated neuron population, and the second frequency provided to reset the phase of the neuronal brain activity in a second sub-population of the stimulated neuron population.

Abstract: A description is given of a method to treat dementia, in particular Alzheimer's disease, Lewy body dementia and vascular dementia, by means of electrical brain stimulation.

Abstract: The present invention is related to a structural protein of a parvovirus with an amino acid insertion at the insertion site I-453, a library comprising the protein, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a vector, virus, or cell comprising the nucleic acid, a process for the preparation of the protein, a medicament comprising the protein, nucleic acid, or multimeric structure as well as methods and uses involving the protein, nucleic acid, or multimeric structure.

Abstract: A device and method for desynchronizing a patient's neuronal brain activity involving a neuron population firing in a pathologically synchronized manner. The device includes a stimulation unit configured to generate an acoustic stimulation signal to stimulate the neuron population when the acoustic stimulation signal is aurally received by the patient. Furthermore, the acoustic stimulation signal has a first frequency and a second frequency, with the first frequency provided to reset the phase of the neuronal brain activity in a first sub-population of the stimulated neuron population, and the second frequency provided to reset the phase of the neuronal brain activity in a second sub-population of the stimulated neuron population.